GS
VRTX icon

GTS Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

GTS Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,100
Closed -$6.56M – 4075
2024
Q3 		$6.56M Sell
14,100
-6,500
-32% -$3.12M 0.01% 724
2024
Q2 		$9.66M Sell
20,600
-3,100
-13% -$1.35M 0.02% 509
2024
Q1 		$9.91M Sell
23,700
-3,300
-12% -$1.4M 0.02% 518
2023
Q4 		$11M Buy
27,000
+2,200
+9% +$813K 0.02% 563
2023
Q3 		$8.62M Buy
+24,800
New +$8.67M 0.02% 660

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GTS Securities's VRTX Position: Q1 2026 in Review

GTS Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q1 2026, selling an estimated $412K and leaving 1,738 shares worth $776K. The position accounts for 0.03% of the portfolio, ranked #498.

GTS Securities first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.58M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • GTS Securities held 1,738 shares of Vertex Pharmaceuticals worth $776K as of Q1 2026.
  • GTS Securities sold 884 Vertex Pharmaceuticals shares in Q1 2026, an estimated $412K.
  • Vertex Pharmaceuticals made up 0.03% of GTS Securities's portfolio in Q1 2026, its #498 holding.
  • GTS Securities first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • GTS Securities's Vertex Pharmaceuticals position peaked at $2.58M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.